Singapore – Oral Presentations and PostersAlexandre Le Vert to provide clinical results of OVX836 as part of a presentation entitled “A novel universal influenza A vaccine candidate: a Phase 1 clinical trial in humans”. Delphine Guyon-Gellin and Nicolas Noulin (hVIVO) to present “Pre-existing NP specific T-cell response correlates with reduction of symptoms in a human …
Author archives: Marianne Duparc
Influenza Vaccines for the World
Edinburgh – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide preclinical results of OVX836 as part of a presentation entitled “OVX836 protects mice in lethal challenges with multiples strains of influenza A viruses”.
World Influenza Conference
Beijing – PosterAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to present preclinical results of OVX836 as part of a poster entitled “OVX836 a multimerized nucleoprotein based vaccine candidate protects mice against lethal challenges of multiple strains of influenza A viruses”.
Universal Influenza Vaccines
Lausanne – Oral PresentationDr. Fergal Hill, Co-founder of Osivax, to provide preclinical results of OVX836 as part of a presentation entitled “OVX836, a multimerized nucleoprotein (NP) induces cellular responses against NP in various animal models challenges of multiple strains of influenza A viruses”.